Glaxo, Theravance File Asthma Drug Application with FDA – NASDAQ

Glaxo, Theravance File Asthma Drug Application with FDA
NASDAQ
LONDON–GlaxoSmithKline PLC (GSK.LN) and Theravance Inc. ( THRX ) have submitted a supplemental new drug application to the U.S. Food and Drug Administration for a drug used for treatment of asthma in patients aged 12 years and older. The British …
GSK and Theravance Announce Submission to US Regulatory Authorities for …MarketWatch
Glaxo And Theravance Submits Supplemental NDA For Breo ElliptaLondon South East

all 3 news articles »